HQL — Tekla Life Sciences Investors stock price, charts and financials

QT76Tekla Life Sciences Investors

Tekla Life Sciences Investors (NYSE: HQL) is a Financial Services company in the Asset Management industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
19.57
+0.29+1.50%
HQLQT76Tekla Life Sciences Investors·NYSE
19.57+1.50%
TA
Loading chart...
Screen all →
Snapshot
Index-P/E2.90EPS (ttm)6.75Insider Own12.04%Shs Outstand30.41MPerf Week-1.11%
Market Cap595.08MForward P/E-EPS next Y-Insider Trans0.01%Shs Float27.44MPerf Month-9.90%
Enterprise Value596.08MPEG0.00EPS next Q-Inst Own-Short Float0.37%Perf Quarter9.57%
Income198.00MP/S9.92EPS this Y-Inst Trans-Short Ratio0.67Perf Half Y19.33%
Sales60.00MP/B1.14EPS next Y-ROA35.18%Short Interest100.18KPerf YTD16.63%
Book/sh17.20P/C-EPS next 5Y-ROE36.89%52W High22.67 -13.67%Perf Year40.39%
Cash/sh0.00P/FCF-EPS past 3/5Y- -10.52%ROIC35.24%52W Low13.90 40.79%Perf 3Y52.06%
Dividend Est.2.48 (12.67%)EV/EBITDA3.01Sales past 3/5Y39.03% 17.14%Gross Margin90.69%Volatility2.22% 2.28%Perf 5Y-11.73%
Dividend TTM2.24 (11.45%)EV/Sales9.93EPS Y/Y TTM122.04%Oper. Margin-ATR (14)0.49Perf 10Y4.04%
Dividend Ex-DateAug 24, 2026Quick Ratio2.58Sales Y/Y TTM-31.03%Profit Margin-RSI (14)37.26Recom-
Dividend Gr. 3/5Y10.20% 3.13%Current Ratio2.58EPS Q/Q-226.82%SMA20-5.55%Beta0.71Target Price-
Payout25.13%Debt/Eq0.00Sales Q/Q2300.00%SMA50-4.09%Rel Volume0.81Prev Close19.28
Employees-LT Debt/Eq0.00Earnings-SMA2008.36%Avg Volume154.30KPrice19.57
IPO DateMay 01, 1992Option/ShortYes / YesEPS/Sales Surpr.-Net Debt/EBITDA0.00Volume124,620Change1.50%
Latest News· Times ET
Sep-15-26
Aug-29-26
Aug-13-26
Jul-25-26
Jul-10-26
Jul-10-2609:07PM
Jul-03-26
Jul-03-2607:01AM
Company

Tekla Life Sciences Investors, a closed-ended equity mutual fund, is expertly managed by Tekla Capital Management LLC. This U.S.-domiciled fund, which commenced operations on February 20, 1992, and was formerly known as H&Q Life Sciences Investors, seeks investment opportunities in publicly traded companies worldwide. Its primary focus lies within the broad life sciences sector, encompassing a diverse range of industries such as biotechnology, pharmaceuticals, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, and medical devices and supplies. The fund also extends its investment purview to include the agriculture and environmental management sectors. It predominantly allocates capital to growth-oriented businesses, particularly those with small market capitalizations. Investment decisions are rooted in rigorous fundamental analysis, which assesses critical factors like a company's market position for its offerings, the acumen of its management team, its technological prowess, and its capability to either self-finance expansion or attract external funding to build its portfolio. The fund's performance is gauged against two key benchmarks: the NASDAQ Biotech Index and the S&P 500 Index.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
FY 2025
9/30/2025
FY 2024
9/30/2024
FY 2023
9/30/2023
FY 2022
9/30/2022
FY 2021
9/30/2021
FY 2020
9/30/2020
FY 2019
9/30/2019
FY 2018
9/30/2018
Total Revenue608687
Cost of Goods Sold Incl. D&A555
Gross Profit548687
Selling, General and Administrative Excl. Other411
Research and Development
000
Other Operating Expense
-14800
Operating Income1988685
Interest Expense
000
Unusual Expense
Non-Operating Income (Expense)
000
Net Income Before Taxes1988685
Income Taxes
000
Consolidated Net Income1988685
Net Income From Continuing Operations1988685
Net Income1988685
EPS (Recurring)6.752.963.04
EPS (Basic, Before Extraordinaries)6.752.963.04
EPS (Diluted)6.752.963.04
EBITDA1988687
Other After Tax Adjustments
Stock Option Compensation Expense
Price To Earnings Ratio2.905.244.96
Price To Sales Ratio9.795.234.85
Gross Margin90.00100.00100.00
Operating Margin330.00100.0097.70
Net Margin330.00100.0097.70
Shares Outstanding302928
Market Capitalization587450422
Operating Lease Expense
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$24.13$20.97$17.82$14.66$11.50 Close Price0.00M0.51M1.02M1.53M2.04MUSD Trades VolumeSepOctNovDec2026FebMarAprMayJunJulAugSep
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Mahai Chris LaVictoireDirectorJul 16 '26Buy19.9252710,498527Jul 20
Pittard ChristianDirectorDec 16 '25Buy16.887,923133,7557,923Dec 18
Saba Capital Management, L.P.10% OwnerSep 22 '25Sale14.1441,623588,5492,837,633Sep 23
Saba Capital Management, L.P.10% OwnerSep 19 '25Sale14.106,98998,5452,879,256Sep 23
Saba Capital Management, L.P.10% OwnerSep 18 '25Sale14.0740,208565,7272,886,245Sep 19
Saba Capital Management, L.P.10% OwnerSep 17 '25Sale13.9924,328340,3492,926,453Sep 19
Saba Capital Management, L.P.10% OwnerSep 16 '25Sale13.992,02628,3442,950,781Sep 17
Saba Capital Management, L.P.10% OwnerSep 15 '25Sale14.137009,8912,952,807Sep 17
Saba Capital Management, L.P.10% OwnerSep 11 '25Sale14.2815,116215,8562,953,507Sep 15
Saba Capital Management, L.P.10% OwnerSep 02 '25Sale14.0414,083197,7252,968,623Sep 04
Saba Capital Management, L.P.10% OwnerAug 29 '25Sale13.8923,723329,5122,982,706Sep 02
Saba Capital Management, L.P.10% OwnerAug 26 '25Sale13.834005,5323,006,429Aug 27
Saba Capital Management, L.P.10% OwnerAug 21 '25Sale14.0710,710150,6903,006,829Aug 25
Saba Capital Management, L.P.10% OwnerMay 20 '25Sale12.7111,419145,1353,017,539May 22
Saba Capital Management, L.P.10% OwnerMay 15 '25Sale12.0823,729286,6463,028,958May 19
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.